Peer Reviewed
Drug update
Sacubitril–valsartan: changing the paradigm for heart failure with reduced ejection fraction
Recent articles on:
Heart failure
Heart failure
Recent articles on:
Heart diseases
Heart diseases
Abstract
Sacubitril–valsartan represents a new drug class, the angiotensin receptor–neprilysin inhibitors, that shows potential to replace ACE inhibitors in the treatment of selected patients with heart failure with reduced ejection fraction.
Key Points
Following the recent PARADIGM-HF trial involving sacubitril–valsartan, recommendations on the optimal medical therapy for a significant proportion of patients with heart failure may be on the cusp of change.1,2 The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan has potential to replace ACE inhibitors in the treatment of selected patients with heart failure with reduced ejection fraction.
Picture credit: © Lightsource/Depositphotos.
Purchase the PDF version of this article
Already a subscriber? Login here.